Outlook Therapeutics files for permanent J-code for Lytenava with CMS

Go back to Outlook Therapeutics files for permanent J-code for Lytenava with CMS

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

October 1, 2026 9:01 AM EDT

Application represents an important step in supporting reimbursement

Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026

ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced... More